A case of occult bowel perforation after a cycle of chemotherapy for advanced epithelial ovarian carcinoma

Occult bowel perforation is a rare complication in chemotherapy of advanced epithelial ovarian cancer (EOC). The authors present a case of a 75-year-old woman who had appendectomy due to suppurative appendicitis five years prior, that experienced an occult bowel perforation resulting in continuous decline of electrolytes after a single cycle of nedaplatin (NDP) and paclitaxel during neoadjuvant treatment of advanced EOC. To the authors' knowledge, this is the first reported case of an occult bowel perforation after neoadjuvant chemotherapy (NAC) for ovarian cancer. The complication was highly suggestive of a cell lysis mechanism for the perforation.

Advanced epithelial ovarian cancer; Occult bowel perforation; Electrolytes; Neoadjuvant chemotherapy; Nedaplatin; Celllysis; CA 125

[1] Jemal A., Siegel R., Xu J., Ward E.: “Cancer statistics, 2010”. CA Cancer J. Clin., 2010, 60, 277.

[2] Colombo N., Peiretti M., Parma G., Lapresa M., Mancari R., Carinelli S. et al.: “Newly diagnosed and relapsed epithelial ovarian carcinoma: Esmo clinical practice guidelines for diagnosis, treatment and follow-up”. Ann. Oncol., 2010, 21 (suppl. 5), v23.

[3] Heintz A.P., Odicino F., Maisonneuve P., Quinn M.A., Benedet J.L., Creasman W.T. et al.: “Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer”. Int. J. Gynaecol. Obstet., 2006, 95 (suppl. 1), S161.

[4] Pignata S., Cannella L., Leopardo D., Pisano C., Bruni G.S., Facchini G.: “Chemotherapy in epithelial ovarian cancer”. Cancer Lett., 2011, 303, 73.

[5] Vergote I., Trope C.G., Amant F., Kristensen G.B., Ehlen T., Johnson N. et al.: “Neoadjuvant chemotherapy or primary surgery in Stage IIIC or iv ovarian cancer”. N. Engl. J. Med., 2010, 363, 943.

[6] Rose P.G., Piver M.S.: “Intestinal perforation secondary to paclitaxel”. Gynecol. Oncol., 1995, 57, 270.

[7] Seewaldt V.L., Cain J.M., Goff B.A., Tamimi H., Greer B., Figge D.: “A retrospective review of paclitaxel-associated gastrointestinal necrosis in patients with epithelial ovarian cancer”. Gynecol. Oncol., 1997, 67, 137.

[8] Carter J., Durfee J.: “A case of bowel perforation after neoadjuvant chemotherapy for advanced epithelial ovarian cancer”. Gynecol. Oncol., 2007, 107, 586.

[9] Han E.S., Monk B.J.: “What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?”. Gynecol. Oncol., 2007, 105, 3.

[10] Torosian M.H., Turnbull A.D.: “Emergency laparotomy for spontaneous intestinal and colonic perforations in cancer patients receiving corticosteroids and chemotherapy”. J. Clin. Oncol., 1988, 6, 291.

[11] Vose J.M., Link B.K., Grossbard M.L., Czuczman M., Grillo-Lopez A., Fisher R.I.: “Long-term update of a phase ii study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-hodgkin's lymphoma”. Leuk Lymphoma, 2005, 46, 1569.

[12] Vose J.M., Link B.K., Grossbard M.L., Czuczman M., Grillo-Lopez A., Gilman P. et al.: “Phase ii study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-hodgkin’s lymphoma”. J. Clin. Oncol., 2001, 19, 389.

[13] García-Sáenz J.A., Custodio A., Casado A., Vidart J.A., Coronado P.J., Martín M. et al.: “Platinum-based adjuvant chemotherapy on moderate- and high-risk stage i and ii epithelian ovarian cancer patients. Long-term single institution experience and literature review”. Clin. Transl. Oncol., 2011, 13, 121.

[14] Rose P.G., Nerenstone S., Brady M.F., Clarke-Pearson D., Olt G., Rubin S.C. et al.: “Secondary surgical cytoreduction for advanced ovarian carcinoma”. N. Engl. J. Med., 2004, 351, 2489.

[15] Ibeanu O.A., Bristow R.E.: “Predicting the outcome of cytoreductive surgery for advanced ovarian cancer: A review”. Int. J. Gynecol. Cancer, 2010, 20 (suppl. 1), S1.

[16] Ranpura V., Hapani S., Wu S.: “Treatment-related mortality with bevacizumab in cancer patients: A meta-analysis”. JAMA, 2011, 305, 487.

[17] Asmis T.R., Capanu M., Kelsen D.P., Shah M.A.: “Systemic chemotherapy does not increase the risk of gastrointestinal perforation”. Ann. Oncol., 2007, 18, 2006.

[18] Kasakura Y., Ajani J.A., Mochizuki F., Morishita Y., Fujii M., Takayama T.: “Outcomes after emergency surgery for gastric perforation or severe bleeding in patients with gastric cancer”. J. Surg. Oncol., 2002, 80, 181.

[19] Yokota T., Yamada Y., Murakami Y., Yasuda M., Kunii Y., Yamauchi H. et al.: “Abdominal crisis caused by perforation of ileal lymphoma”. Am. J. Emerg. Med., 2002, 20, 136.

[20] Ramirez P.T., Levenback C., Burke T.W., Eifel P., Wolf J.K., Gershenson D.M.: “Sigmoid perforation following radiation therapy in patients with cervical cancer”. Gynecol. Oncol., 2001, 82, 150.